Journal ArticleDOI
Abnormal tau in amyloid PET negative individuals.
Bora Yoon,Tengfei Guo,Tengfei Guo,Karine Provost,Deniz Korman,Tyler J. Ward,Susan M. Landau,William J. Jagust,William J. Jagust,Alzheimer's Disease Neuroimaging Initiative +9 more
TLDR
The authors examined the characteristics of individuals with biomarker evidence of tauopathy but without β-amyloid (Aβ) (A-T+) in relation to individuals with (A+T+) and without (A-) evidence of Alzheimer's disease (AD).About:
This article is published in Neurobiology of Aging.The article was published on 2022-01-01. It has received 12 citations till now. The article focuses on the topics: Tauopathy & Temporal lobe.read more
Citations
More filters
Journal ArticleDOI
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Cherie Strikwerda-Brown,Diana A. Hobbs,Julie Gonneaud,Frédéric St-Onge,Alexa Pichet Binette,Hazal Ozlen,Karine Provost,Jean-Paul Soucy,Rachel F. Buckley,Tammie L.S. Benzinger,John C. Morris,Victor L. Villemagne,Vincent Dorcet,Reisa A. Sperling,Keith A. Johnson,Christopher C. Rowe,Brian A. Gordon,Judes Poirier,John C.S. Breitner,Sylvia Villeneuve +19 more
TL;DR: The clinical prognostic value of NIA-AA research criteria was confirmed in 4 independent cohorts, with most A+T+(N+) older individuals without cognitive impairment developing AD symptoms within 2 to 3 years.
Journal ArticleDOI
Hypothesis review: Alzheimer's overture guidelines
TL;DR: The National Institute on Aging-Alzheimer's Association definition and classification of sporadic Alzheimer's disease (sAD) is based on the assumption that β-amyloid drives the pathogenesis of sAD, and therefore, β-AMyloid pathology is the sinequa-non condition for the diagnosis of SAD as discussed by the authors , however, NFTs develop in the brain decades before the appearance of senile plaques and their distribution does not parallel the distribution of SPs.
Posted ContentDOI
AT(N) predicts near-term development of Alzheimer's disease symptoms in unimpaired older adults
Cherie Strikwerda-Brown,Julie Gonneaud,Derek Hobbs,Frédéric St-Onge,Alexa Pichet Binette,Hazal Ozlen,Karine Provost,Jean-Paul Soucy,Rachel F. Buckley,Tammie L.S. Benzinger,John C. Morris,Victor L. Villemagne,Vincent Dorcet,Reisa A. Sperling,Keith A. Johnson,Christopher C. Rowe,Brian A. Gordon,Judes Poirier,Jcs Breitner,Sarah-Christine Villeneuve,Aibl,Knight ADRC,Habs,PREVENT-AD +23 more
TL;DR: In this paper , the clinical value of these biological criteria for prediction of near-term cognitive impairment in cognitively unimpaired older individuals was assessed using temporal cortical thickness, which was confirmed in four independent cohorts, with nearly all A+T+ individuals developing AD symptoms within 2-3 years.
Journal ArticleDOI
Clear‐headed into old age: Resilience and resistance against brain aging—A PET imaging perspective
Merle C Hoenig,Alexander Drzezga +1 more
TL;DR: Better understanding of the underlying mechanisms of resilience and resistance may one day, hopefully, support the identification of defeating mechanism against accelerating aging.
Journal ArticleDOI
Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.
TL;DR: A major point of clinical discussion has been, and still is, establishing the differences between brain aging and sAD as discussed by the authors , and the first appearance of early stages of sAD-related pathology are not easily distinguishable in most individuals.
References
More filters
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.
TL;DR: To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis.
Journal ArticleDOI
Staging of Alzheimer's disease-related neurofibrillary changes.
Heiko Braak,Eva Braak +1 more
TL;DR: Specific immunocytochemical methods (AT8) permit evaluation of neuronal changes well before the actual formation of neurofibrillary tangles and neuropil threads, which facilitates recognition of even subtle pathologic changes throughout the entire extent of cortical territories such as the transentorhinal and entorHinal regions.
Journal ArticleDOI
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Howard Feldman,Giovanni B. Frisoni,Harald Hampel,William J. Jagust,Keith A. Johnson,David S. Knopman,Ronald C. Petersen,Philip Scheltens,Reisa A. Sperling,Bruno Dubois +13 more
TL;DR: This work proposes the “A/T/N” system, a descriptive system for categorizing multidomain biomarker findings at the individual person level in a format that is easy to understand and use and suited to population studies of cognitive aging.
Related Papers (5)
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Clifford R. Jack,Heather J. Wiste,Hugo Botha,Stephen D. Weigand,Terry M. Therneau,David S. Knopman,Jonathan Graff-Radford,David T.W. Jones,Tanis J. Ferman,Bradley F. Boeve,Kejal Kantarci,Val J. Lowe,Prashanthi Vemuri,Michelle M. Mielke,Julie A. Fields,Mary M. Machulda,Christopher G. Schwarz,Matthew L. Senjem,Jeffrey L. Gunter,Ronald C. Petersen +19 more
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Joseph Therriault,Joseph Therriault,Andrea Lessa Benedet,Andrea Lessa Benedet,Tharick A. Pascoal,Tharick A. Pascoal,Sulantha Mathotaarachchi,Mira Chamoun,Melissa Savard,Emilie Thomas,Min Su Kang,Min Su Kang,Firoza Z. Lussier,Firoza Z. Lussier,Cecile Tissot,Cecile Tissot,Marlee Parsons,Marlee Parsons,Muhammad Naveed Iqbal Qureshi,Paolo Vitali,Gassan Massarweh,Gassan Massarweh,Jean-Paul Soucy,Jean-Paul Soucy,Soham Rej,Paramita Saha-Chaudhuri,Serge Gauthier,Pedro Rosa-Neto +27 more